Link
Managing Immune Checkpoint Inhibitor-Induced Psoriasis: Inference-Based Guidance for Safe Use of Systemic Therapies.
This commentary from IPC Board Member Lluís Puig examines inference-based guidance for managing immune checkpoint…
This commentary from IPC Board Member Lluís Puig examines inference-based guidance for managing immune checkpoint…
View MoreThis commentary from IPC Board Member Lluís Puig examines inference-based guidance for managing immune checkpoint…
Read MoreThe International Psoriasis Council (IPC) and the National Psoriasis Foundation (NPC) have released a joint position…
View ReportThe 33rd Annual EADV Congress in Amsterdam featured updates on psoriasis care, including highlights from the IPC…
Read MoreGeneralized pustular psoriasis(GPP)lacks internationally accepted definitions and diagnostic criteria, impeding timely…
View ReportThis commentary provides expert analysis on recent research findings, clinical trial results, and the promising future…
Read MoreDr. Lluís Puig examines the evolving treatment landscape for psoriasis and discusses various treatment and therapy…
Watch VideoROMANIAN ASSOCIATION OF DERMATOLOGY & VENEREOLOGY (ARDV) ANNUAL CONGRESS | BUCHAREST, ROMANIA Friday, November…
ACADEMIA ESPAÑOLA DE DERMATOLOGÍA Y VENEREOLOGÍA (AEDV) CONGRESS | MADRID, SPAIN Thursday, January 18 18:00 -…
This is the second webinar of the IPC Global Webinar Series. It focuses on psoriasis and cancer or chronic infections.
Watch VideoIPC GLOBAL WEBINAR SERIES April 18 3:30 pm - 4:30 pm CEST 9:30 am - 10:30 am EDT Program chair: Lluís Puig,…
The European Academy of Dermatology and Venereology (EADV) organized its 31st congress in Milano, Italy, under the…
Read MoreEUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (EADV) | BERLIN, GERMANY Wednesday, October 11 8:30 – 11:45 am…
In the final webinar in the series, we will explore lessons from the SARS-CoV-2 pandemic and how we can prepare for…
Watch VideoThe European Academy of Dermatology and Venerelogy 30th Annual Congress (EADV) was packed with science and clinical…
Read MoreThomas Sharnitz, MD, has written the report, summarizing the most important presentations with a focus on psoriasis…
View ReportView Report
Dr. Lluís Puig provides his comments on a recent publication on the classification of the cutaneous manifestations of…
Read MoreView Report
| Cookie | Duration | Description |
|---|---|---|
| cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
| cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
| cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
| cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
| cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
| viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
IPC Councilor Helen Young provides commentary on a study identifying skin-derived myeloid precursors and CD200+ fibroblasts as key drivers of psoriatic disease spread from the skin to joints, highlighting the CD200–CD200R1 axis as a promising therapeutic target.
IPC Fellow Dr. Yemsrach Abawaji shares her firsthand perspective on the barriers to psoriasis diagnosis and treatment in Ethiopia and opportunities to improve care.
Did you miss the IPC symposium at the 83rd Society for Investigative Dermatology (SID) Annual Meeting? Select session videos are now available. The Arc of Disease Control in Psoriasis: Early Interception – Deep Pathway Blockade – Treatment Failure covered early intervention strategies, treatment selection, immune pathway targeting, PsA prevention, clinical escape, and real-world cases that inform long-term psoriasis care.
Depression affects approximately 20% of patients with psoriasis, five times the rate seen in the general population. IPC Jr. Councilor Mio Nakamura, MD, MS, FAAD, walks through the bidirectional relationship between psoriasis and depression, the shared inflammatory pathways driving both conditions, and practical guidance on screening and incorporating multidisciplinary mental health support into psoriasis management.